Esq JD - Erasca General Secretary

All Insiders . USA . 
Stock . Erasca Inc . Stakeholders . Insider . Esq JD
ERAS Stock  USD 2.70  0.10  3.85%   

Executive

Esq JD is General Secretary of Erasca Inc
Age 52
Address 3115 Merryfield Row, San Diego, CA, United States, 92121
Phone858 465 6511
Webhttps://www.erasca.com

Erasca Management Efficiency

The company has return on total asset (ROA) of (0.1914) % which means that it has lost $0.1914 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.389) %, meaning that it created substantial loss on money invested by shareholders. Erasca's management efficiency ratios could be used to measure how well Erasca manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2024. Return On Capital Employed is likely to drop to -0.4 in 2024. Net Tangible Assets is likely to gain to about 497.3 M in 2024, whereas Total Assets are likely to drop slightly above 350.2 M in 2024.
Erasca Inc currently holds 55.86 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Erasca Inc has a current ratio of 16.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Erasca's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Vineeta BelangerLyra Therapeutics
N/A
Robert RichardLyra Therapeutics
66
Corinne NoyesLyra Therapeutics
56
Carlos CarilloSAB Biotherapeutics
N/A
Cheston TurbyfillCoherus BioSciences
N/A
Gloria CosgroveLyra Therapeutics
N/A
Ray KnoxLyra Therapeutics
N/A
MD MBASAB Biotherapeutics
51
Robert MDLyra Therapeutics
N/A
Richard MDLyra Therapeutics
61
Michael ChenCoherus BioSciences
N/A
Jeff ColeCadrenal Therapeutics, Common
N/A
Ellen CavaleriLyra Therapeutics
N/A
Allison NanceLyra Therapeutics
N/A
Scott SaywellCoherus BioSciences
N/A
Andy RittenbergCoherus BioSciences
N/A
Daniel CourtneyHookipa Pharma
N/A
MRCP MDCoherus BioSciences
55
Mark WinderlichHookipa Pharma
38
Jami TaylorCoherus BioSciences
N/A
Michael SzumeraHookipa Pharma
N/A
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers. The company was incorporated in 2018 and is headquartered in San Diego, California. Erasca operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people. Erasca Inc (ERAS) is traded on NASDAQ Exchange in USA. It is located in 3115 Merryfield Row, San Diego, CA, United States, 92121 and employs 126 people. Erasca is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-0.39
Return On Asset-0.19

Erasca Inc Leadership Team

Elected by the shareholders, the Erasca's board of directors comprises two types of representatives: Erasca inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Erasca. The board's role is to monitor Erasca's management team and ensure that shareholders' interests are well served. Erasca's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Erasca's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Varney, Scientific Development
Lisa TesvichBonora, Chief Officer
Nik Chetwyn, VP Operations
CPA MS, VP Fin
Wei MD, Chief Officer
JD Esq, General Secretary
Esq JD, General Secretary
Chandra Lovejoy, VP Affairs
Chandra MS, Chief Officer
MS CPA, Senior Finance
David MD, Chief Officer
Jonathan MD, Chairman CoFounder
Robert Shoemaker, Senior Research

Erasca Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Erasca a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.39
Return On Asset-0.19
Current Valuation469.12 M
Shares Outstanding282.73 M
Shares Owned By Insiders12.39 %
Shares Owned By Institutions86.99 %
Number Of Shares Shorted32.97 M
Price To Book1.63 X
EBITDA(121.31 M)
Net Income(125.04 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Erasca Stock Analysis

When running Erasca's price analysis, check to measure Erasca's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Erasca is operating at the current time. Most of Erasca's value examination focuses on studying past and present price action to predict the probability of Erasca's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Erasca's price. Additionally, you may evaluate how the addition of Erasca to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY